BOM:524715 (India)
Â
Ordinary Shares
₹
1,973.5
+32.5 (+1.67%)
Jul 27
Business Description
Sun Pharmaceuticals Industries Ltd
ISIN : INE044A01036
Share Class Description:
BOM:524715: Ordinary SharesTotal Employee Number:
19,297Compare
Compare
Traded in other countries / regions
SUNPHARMA.India Index Membership
BSE SENSEX IPO Date
1994-12-19Description
Sun Pharmaceuticals Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulation and Active Pharmaceutical ingredients(APIs). The Company has various manufacturing locations spread across the country with trading and other incidental and related activities extending to the world-wide market. The company's reportable segments are India, United States of America, Emerging markets, and Rest of the world. The company generates majority of revenue from India. Its products are Speciality Medications, Generic Medications, Over-the-Counter Medications, Active Pharmaceutical Ingredients, and Anti Retro Viral Medications.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 7.3 | |||||
Equity-to-Asset | 0.77 | |||||
Debt-to-Equity | 0.06 | |||||
Debt-to-EBITDA | 0.25 | |||||
Interest Coverage | 39.99 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 13.57 | |||||
Beneish M-Score | -2.39 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 10.4 | |||||
3-Year EBITDA Growth Rate | 15 | |||||
3-Year EPS without NRI Growth Rate | 11 | |||||
3-Year FCF Growth Rate | 45.3 | |||||
3-Year Book Growth Rate | 14.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 14.3 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 13.42 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 67.67 | |||||
9-Day RSI | 66.41 | |||||
14-Day RSI | 65.75 | |||||
3-1 Month Momentum % | 7.4 | |||||
6-1 Month Momentum % | 13.59 | |||||
12-1 Month Momentum % | 9.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.82 | |||||
Quick Ratio | 2.32 | |||||
Cash Ratio | 1.49 | |||||
Days Inventory | 339.15 | |||||
Days Sales Outstanding | 91.85 | |||||
Days Payable | 213.15 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.82 | |||||
Dividend Payout Ratio | 0.32 | |||||
3-Year Dividend Growth Rate | 16.3 | |||||
Forward Dividend Yield % | 0.82 | |||||
5-Year Yield-on-Cost % | 2.07 | |||||
Shareholder Yield % | 0.29 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 80.17 | |||||
Operating Margin % | 23.28 | |||||
Net Margin % | 19.72 | |||||
EBITDA Margin % | 31.6 | |||||
FCF Margin % | 15.13 | |||||
OCF Margin % | 21.33 | |||||
ROE % | 14.74 | |||||
ROA % | 11.31 | |||||
ROIC % | 16.29 | |||||
3-Year ROIIC % | 26.66 | |||||
ROC (Joel Greenblatt) % | 66.31 | |||||
ROCE % | 19.29 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 41.29 | |||||
Forward PE Ratio | 35.59 | |||||
PE Ratio without NRI | 38.02 | |||||
Shiller PE Ratio | 63.47 | |||||
Price-to-Owner-Earnings | 39.55 | |||||
PEG Ratio | 1.24 | |||||
PS Ratio | 8.14 | |||||
PB Ratio | 5.66 | |||||
Price-to-Tangible-Book | 7.87 | |||||
Price-to-Free-Cash-Flow | 53.76 | |||||
Price-to-Operating-Cash-Flow | 38.13 | |||||
EV-to-EBIT | 28.77 | |||||
EV-to-Forward-EBIT | 24.52 | |||||
EV-to-EBITDA | 24.18 | |||||
EV-to-Forward-EBITDA | 20.05 | |||||
EV-to-Revenue | 7.63 | |||||
EV-to-Forward-Revenue | 5.72 | |||||
EV-to-FCF | 49.59 | |||||
Price-to-GF-Value | 1.02 | |||||
Price-to-Projected-FCF | 2.7 | |||||
Price-to-Median-PS-Value | 1.5 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.55 | |||||
Price-to-Graham-Number | 3.65 | |||||
| Price-to-Net-Current-Asset-Value | 12.24 | |||||
| Price-to-Net-Cash | 55.28 | |||||
Earnings Yield (Greenblatt) % | 3.48 | |||||
FCF Yield % | 1.86 | |||||
Forward Rate of Return (Yacktman) % | 21.65 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sun Pharmaceuticals Industries Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 582,201.1 | ||
| EPS (TTM) (₹) | 47.8 | ||
| Beta | 0.7386 | ||
| 3-Year Sharpe Ratio | 0.65 | ||
| 3-Year Sortino Ratio | 1.09 | ||
| Volatility % | 19.32 | ||
| 14-Day RSI | 65.75 | ||
| 14-Day ATR (₹) | 32.059487 | ||
| 20-Day SMA (₹) | 1925.6325 | ||
| 12-1 Month Momentum % | 9.63 | ||
| 52-Week Range (₹) | 1547.25 - 1977 | ||
| Shares Outstanding (Mil) | 2,399.33 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sun Pharmaceuticals Industries Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sun Pharmaceuticals Industries Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2027 | 2026-11-05 18:30 | In 102 days | ||
| Second quarter earnings results for 2027 | 2026-11-05 | In 100 days | ||
| First quarter earnings conference call for 2027 | 2026-07-31 18:30 | In 4 days | ||
| General meeting for 2026 | 2026-07-31 16:00 | In 4 days | ||
| First quarter earnings results for 2027 | 2026-07-31 | In 3 days | ||
| INR 5.000000 Cash Dividend | 2026-07-07 | 1,913.05 (+0.16%) | ||
| Annual report for 2026 | 2026-07-06 | 1,904.65 (+1.85%) | ||
| Fourth quarter earnings conference call for 2026 | 2026-05-22 18:30 | 1,891.15 (+0.16%) | ||
| Fourth quarter earnings results for 2026 | 2026-05-22 | 1,891.15 (+0.16%) | ||
| INR 11.000000 Cash Dividend | 2026-02-05 | 1,704.00 (-0.11%) |
Show
Entries
Sun Pharmaceuticals Industries Ltd Frequently Asked Questions
What is Sun Pharmaceuticals Industries Ltd(BOM:524715)'s stock price today?
The current price of BOM:524715 is ₹1973.50. The 52 week high of BOM:524715 is ₹1977.00 and 52 week low is ₹1547.25.
When is next earnings date of Sun Pharmaceuticals Industries Ltd(BOM:524715)?
The next earnings date of Sun Pharmaceuticals Industries Ltd(BOM:524715) is 2026-07-31.
Does Sun Pharmaceuticals Industries Ltd(BOM:524715) pay dividends? If so, how much?
The Dividend Yield %  of Sun Pharmaceuticals Industries Ltd(BOM:524715) is 0.82% (As of Today), Highest Dividend Payout Ratio of Sun Pharmaceuticals Industries Ltd(BOM:524715) was 0.35. The lowest was 0.04. And the median was 0.31. The  Forward Dividend Yield % of Sun Pharmaceuticals Industries Ltd(BOM:524715) is 0.82%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Articles on Sun Pharmaceuticals Industries Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers